Argentina |
Susceptibility data for FCZ and AmB for C. neoformans isolates from HIV-positive patients |
Arechavala et al. (2009)Arechavala AI, Ochiuzzi ME, Borgnia MD, Santiso GM. [Fluconazole and amphotericin B susceptibility testing of Cryptococcus neoformans: results of minimal inhibitory concentrations against 265 isolates from HIV-positive patients before and after two or more months of antifungal therapy]. Rev Iberoam Micol. 2009; 26(3): 194-7.
|
Correlation of ETest and Neo-Sensitabs diffusion assays with broth microdilution reference method (CLSI-M27-A2) for testing susceptibility of C. neoformans to AmB and FCZ |
Ochiuzzi et al. (2010)Ochiuzzi ME, Santiso GM, Arechavala AI. Correlation of Etest and Neo-Sensitabs diffusion assays on Mueller-Hinton-methylene blue agar with broth microdilution reference method (CLSI-M27-A2) for testing susceptibilities of Cryptococcus neoformans to amphotericin B and fluconazole. Med Mycol. 2010; 48(6): 893-6.
|
In vitro activity of AmB B by time-kill curve methodology |
Córdoba et al. (2011)Córdoba S, Afeltra J, Vitale RG. Evaluation of the in vitro activity of amphotericin B by time-kill curve methodology against large and small capsulate C. neoformans isolates. Diagn Microbiol Infect Dis. 2011; 71(3): 260-2.
|
International study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for FCZ, ITZ, PCZ, and VCZ. Argentina, Brazil, Cuba, Mexico |
Espinel-Ingroff et al. (2012a)Espinel-Ingroff A, Aller AI, Canton E, Castanon-Olivares LR, Chowdhary A, Cordoba S, et al. Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole. Antimicrob Agents Chemother. 2012a; 56(11): 5898-906.
|
Comparison of different in vitro tests to detect C. neoformans not susceptible to AmB |
Córdoba et al. (2015)Córdoba S, Vivot W, Szusz W, Isla G, Davel G. Comparison of different in vitro tests to detect Cryptococcus neoformans not susceptible to amphotericin B. Mycopathologia. 2015; 179(5-6): 359-71.
|
Susceptibility profile and epidemiological cut-off values of C. neoformans species complex from Argentina |
Córdoba et al. (2016)Córdoba S, Isla MG, Szusz W, Vivot W, Altamirano R, Davel G. Susceptibility profile and epidemiological cut-off values of Cryptococcus neoformans species complex from Argentina. Mycoses. 2016; 59(6): 351-6.
|
C. neoformans lanosterol 14-α-demethylase involved in fluconazole resistance in clinical isolates |
Bosco-Borgeat et al. (2016)Bosco-Borgeat ME, Mazza M, Taverna CG, Cordoba S, Murisengo OA, Vivot W, et al. Amino acid substitution in Cryptococcus neoformans lanosterol 14-alpha-demethylase involved in fluconazole resistance in clinical isolates. Rev Argent Microbiol. 2016; 48(2): 137-42.
|
Brazil |
An international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for AmB and 5FC in C. neoformans and C. gattii
|
Espinel-Ingroff et al. (2012a)Espinel-Ingroff A, Aller AI, Canton E, Castanon-Olivares LR, Chowdhary A, Cordoba S, et al. Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole. Antimicrob Agents Chemother. 2012a; 56(11): 5898-906.
|
Susceptibility to antifungal agents and genotypes of Brazilian clinical and environmental C. gattii strains |
Silva et al. (2012)da Silva BK, Freire AK, Bentes AS, Sampaio IL, Santos LO, dos Santos MS, et al. Characterization of clinical isolates of the Cryptococcus neoformans-Cryptococcus gattii species complex from the Amazonas state in Brazil. Rev Iberoam Micol. 2012; 29(1): 40-3.
|
Microbiological characteristics of clinical isolates of Cryptococcus spp. in Bahia, Brazil: molecular types and antifungal susceptibilities |
Matos et al. (2012)Matos CS, Andrade AS, Oliveira NS, Barros TF. Microbiological characteristics of clinical isolates of Cryptococcus spp. in Bahia, Brazil: molecular types and antifungal susceptibilities. Eur J Clin Microbiol Infect Dis. 2012; 31(7): 1647-52.
|
Environmental isolation, biochemical identification, and antifungal drug susceptibility of Cryptococcus spp. |
Teodoro et al. (2013)Teodoro VL, Gullo FP, Sardi JC, Torres EM, Fusco-Almeida AM, Mendes-Giannini MJ. Environmental isolation, biochemical identification, and antifungal drug susceptibility of Cryptococcus species. Rev Soc Bras Med Trop. 2013; 46(6): 759-64.
|
Susceptibility profile of clinical and environmental isolates of C. neoformans and C. gattii
|
Andrade-Silva et al. (2013)Andrade-Silva L, Ferreira-Paim K, Mora DJ, da Silva PR, Andrade AA, Araujo NE, et al. Susceptibility profile of clinical and environmental isolates of Cryptococcus neoformans and Cryptococcus gattii in Uberaba, Minas Gerais, Brazil. Med Mycol. 2013; 51(6): 635-40.
|
A flow cytometry method for testing the susceptibility of Cryptococcus spp. to AmB |
Benaducci et al. (2015)Benaducci T, Matsumoto MT, Sardi JC, Fusco-Almeida AM, Mendes-Giannini MJ. A flow cytometry method for testing the susceptibility of Cryptococcus spp. to amphotericin B. Rev Iberoam Micol. 2015; 32(3): 159-63.
|
In vitro susceptibility testing of AmB for C. neoformans variety grubii AFLP1/VNI and C. gattii AFLP6/VGII by CLSI and flow cytometry |
Morales et al. (2015)Morales BP, Trilles L, Bertho AL, Neves Jr I, de Oliveira RVC, Wanke B, et al. In vitro susceptibility testing of amphotericin B for Cryptococcus neoformans variety grubii AFLP1/VNI and Cryptococcus gattii AFLP6/VGII by CLSI and flow cytometry. Mycoses. 2015; 58(5): 273-9.
|
Heteroresistance to ITZ and changes in the morphology and virulence of C. gattii
|
Ferreira et al. (2015)Ferreira GF, Santos JR, Costa MC, Holanda RA, Denadai AM, Freitas GJ, et al. Heteroresistance to Itraconazole alters the morphology and increases the virulence of Cryptococcus gattii. Antimicrob Agents Chemother. 2015; 59(8): 4600-9.
|
Antifungal susceptibility of clinical C. deuterogattii (AFLP6/VGII) isolates from Southern Brazil |
Herkert et al. (2016)Herkert PF, Hagen F, Salvador GLO, Gomes RR, Ferreira MS, Vicente VA, et al. Molecular characterisation and antifungal susceptibility of clinical Cryptococcus deuterogattii (AFLP6/VGII) isolates from Southern Brazil. Eur J Clin Microbiol Infect Dis. 2016; 35(11): 1803-10.
|
Resistance to FCZ and changes on virulence and morphological aspects of C. neoformans and C. gattii
|
Rossi et al. (2016)Rossi SA, Trevijano-Contador N, Scorzoni L, Mesa-Arango AC, de Oliveira HC, Werther K, et al. Impact of resistance to fluconazole on virulence and morphological aspects of Cryptococcus neoformans and Cryptococcus gattii isolates. Front Microbiol. 2016; 7: 153.
|
Antifungal susceptibility testing and genotyping characterization of C. neoformans and C. gattii isolates from HIV-infected patients |
Figueiredo et al. (2016)Figueiredo TP, Lucas RC, Cazzaniga RA, Franca CN, Segato F, Taglialegna R, et al. Antifungal susceptibility testing and genotyping characterization of Cryptococcus neoformans and gattii isolates from HIV-infected patients of Ribeirao Preto, Sao Paulo, Brazil. Rev Inst Med Trop Sao Paulo. 2016; 58: 69.
|
Evaluation of antifungal combination against Cryptococcus spp. |
Reichert-Lima et al. (2016)Reichert-Lima F, Busso-Lopes AF, Lyra L, Peron IH, Taguchi H, Mikami Y, et al. Evaluation of antifungal combination against Cryptococcus spp. Mycoses. 2016; 59(9): 585-93.
|
C. neoformans and C. gattii isolates from both HIV-infected and uninfected patients: antifungal susceptibility and outcome of cryptococcal disease |
Nascimento et al. (2017)Nascimento E, Vitali LH, Kress M, Martinez R. Cryptococcus neoformans and C. gattii isolates from both HIV-infected and uninfected patients: antifungal susceptibility and outcome of cryptococcal disease. Rev Inst Med Trop São Paulo. 2017; 59: e49.
|
FCZ non-susceptible C. neoformans. Use of LAmB in AIDS patient |
Santana et al. (2017)Santana RC, Schiave LA, Quaglio ASS, de Gaitani CM, Martinez R. Fluconazole non-susceptible Cryptococcus neoformans, relapsing/refractory cryptococcosis and long-term use of liposomal Amphotericin B in an AIDS patient. Mycopathologia. 2017; 182(9-10): 855-61.
|
FCZ levels in serum and cerebrospinal fluid |
Schiave et al. (2018)Schiave LA, Nascimento E, Vilar FC, Haes TM, Takayanagui OM, Gaitani CM, et al. Fluconazole levels in serum and cerebrospinal fluid according to daily dosage in patients with cryptococcosis and other fungal infections. Braz J Infect Dis. 2018; 22(1): 11-5.
|
Time-kill curves studies with AmB against C. neoformans/C. gattii species complex clinical isolates |
de Oliveira et al. (2017)de Oliveira L, Silva-Santos DC, Martins MA, Szeszs MW, Melhem MSC. Time-kill curves studies with amphotericin B against Cryptococcus neoformans/C. gattii species complex clinical isolates. Current Fungal Infection Reports. 2017; 11(4): 158-62.
|
Heteroresistance to FCZ in clinical and environmental strains of C. neoformans and C. gattii
|
Feliciano et al. (2017)Feliciano LM, Ramos SDP, Szeszs MW, Martins MA, Bonfietti LX, Oliveira RA, et al. Heteroresistance to fluconazol in clinical and environmental brazilian strains of Cryptococcus neoformans/C. gattii species complex. Current Fungal Infection Reports. 2017; 11(4): 190-6.
|
Cuba |
C. neoformans, FCZ susceptibility |
Fernández-Andreu et al. (1999)Fernández-Andreu CM, Pimentel-Turino T, Martinez-Machin GF, González-Miranda M. Determinación de la concentración mínima inhibitoria de fluconazol frente a Cryptococcus neoformans. Rev Cubana Med Trop. 1999; 51(1): 55-7.
|
New azoles and C. neoformans Cuban clinical isolates |
Illnait-Zaragozi et al. (2008)Illnait-Zaragozi MT, Martinez GF, Curfs-Breuker I, Fernández CM, Boekhout T, Meis JF. In vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba. Antimicrob Agents Chemother. 2008; 52(4): 1580-2.
|
FCZ, VCZ susceptibility of Cuban isolates |
Illnait-Zaragozi et al. (2009)Illnait-Zaragozi MT, Meis JF, Martinez-Machin GF, Curfs-Breuker I, Fernández-Andreu CM, Perurena-Lancha MR. [In vitro susceptibility of isolated Cryptococcus strains to fluconazole and voriconazole]. Rev Cubana Med Trop. 2009; 61(1): 70-4.
|
Venezuela |
A review of C. neoformans ECVs |
Ferrara et al. (2017)Ferrara G, Urdaneta E, Panizo MM, Alarcón V, García N, Moreno X, et al. Molecular characterization of Cryptococcus neoformans and Cryptococcus gattii by PCR-RFLP in Venezuela. In: 10th International Conference on Cryptococcus and Cryptococcosis. Foz do Iguazu: 2017; p. Ep 27.
|